Franklin Biotechnology Discovery Fund A(acc) EUR-H1Register to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 33.4 | -23.3 | -10.3 | 11.9 | 8.4 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 21/11/2024 | EUR 11.79 | |
Day Change | 0.26% | |
Morningstar Category™ | Other Equity | |
ISIN | LU1803069274 | |
Fund Size (Mil) 31/10/2024 | USD 1529.56 | |
Share Class Size (Mil) 21/11/2024 | EUR 9.59 | |
Max Initial Charge | 5.75% | |
Ongoing Charge 31/07/2024 | 1.81% |
Investment Objective: Franklin Biotechnology Discovery Fund A(acc) EUR-H1 |
The Fund’s investment objective is capital appreciation. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Evan McCulloch 01/11/2000 | ||
Akiva Felt 31/01/2020 | ||
Inception Date 06/04/2018 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Franklin Biotechnology Discovery Fund A(acc) EUR-H1 | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Amgen Inc | Healthcare | 6.71 |
Vertex Pharmaceuticals Inc | Healthcare | 6.21 |
Regeneron Pharmaceuticals Inc | Healthcare | 5.92 |
Gilead Sciences Inc | Healthcare | 4.90 |
Intra-Cellular Therapies Inc | Healthcare | 3.42 |
Increase Decrease New since last portfolio | ||
Franklin Biotechnology Discovery Fund A(acc) EUR-H1 |